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Diabetic autonomic neuropathy is a heterogenous syndrome with dif- 
fuse manifestations affecting many organ systems (1). The alteration in 
adrenergic physiology is particularly complicated since some patients 
have low circulating norepinephrine (NE)* levels and a blunted NE re- 
sponse to postural stress, whereas others exhibit high plasma NE and 
an exaggerated response to the assumption of an upright posture (2,3). 
This condition has accordingly been classified into hypoadrenergic and 
hyperadrenergic postural hypotension (3). Little is known about the bio- 
chemical basis for these disorders of adrenergic function, but there is 
pharmacological evidence that in the hypoadrenergic form of this disease, 
the lesion resides in the postganglionic sympathetic neuron (4). The two 
most important catecholamine biosynthetic enzymes in sympathetic neu- 
rons are tyrosine hydroxylase and dopamine P-hydroxylase (DBH) and 
decreased activity of either might lead to decreased NE synthesis (5~5) 
clinically manifested as postural hypotension. It has been suggested that 
an abnormality of the latter enzyme is critical since circulating DBH is 
very low (< 20% of normal) in some patients with diabetic autonomic 
neuropathy (7). In idiopathic orthostatic hypotension also circulating 
DBH levels are low (8) and these patients have difficulty converting 
’ To whom requests for reprints should be sent at: General Clinical Research Center. 
Temple University Hospital, 3401 N. Broad St., Philadelphia, Pa. 19140. 
.’ Abbreviations used: NE, norepinephrine; NMN, normetanephrine; DA, dopamine: 
MTA, methroxytyramine; DHPG, dihydroxyphenylglycol; DHPE. dihydroxyphenyleth- 
anol: DHMA, dihydroxymadelic acid; DOPAC, dihydroxyphenylacetic acid; MHPG. 3- 
methoxy-4-hydroxyphenylglycol; MHPE, 3-methoxy-4-hydroxyphenylethanol; VMA, 3- 
methoxy-4-hydroxymandelic acid; HVA, 3-methoxy-4-hydroxyphenylacetic acid. 
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intravenously administered [‘“Cl dopamine (DA) to [14C]NE (9). The 
present study was undertaken to determine whether the low serum DBH 
reported in patients with diabetic autonomic neuropathy might be indic- 
ative of a deficit in the ability of their sympathetic neurons to convert 
dopamine (DA) to NE. We studied this question with a recently devel- 
oped tritium release assay, specifically designed to assess DBH activity 
in sympathetic neurons (10,ll). 
The tritium-release assay of DBH is based on the in vitro observation 
that when [B-3H]DA is used as substrate for the hydroxylase, a molecule 
of THO is released for each molecule of [3H]NE formed (10). The 
[p - 3H]DA is an equal mixture of (S)-[p - ‘HIDA, whose hydroxylation 
leads to the formation of [3H]NE, and (R)-[P -3H]DA whose hydroxy- 
lation leads to the formation of THO (Scheme 1). 
Since half of the labeled product is in the form of THO and half in 
the form of [3H]NE and its metabolites, it is possible to assay these two 
indices of dopamine B-hydroxylation simultaneously. The measurement 
of THO is of interest since this product of the enzymatic reaction (unlike 
[3H]NE) undergoes neither subsequent metabolism nor reuptake into the 
nerve terminal. 
MATERIALS AND METHODS 
Experimental Protocol 
The 19 participants in this study included seven healthy subjects, six 
diabetics without autonomic neuropathy, and six diabetics with auto- 
nomic neuropathy. The two groups of diabetics were well matched for 
age and sex; the healthy subjects were slightly older (Table 1). All of 
the diabetics were on insulin therapy; two-thirds of the diabetics in each 
group were insulin dependent. The mean FBS for the autonomic neu- 
ropathy patients was 205 1 33 @EM); the mean FBS for the diabetics 
without neuropathy was 156 ? 40. None of the patients had renal in- 
sufficiency (serum creatinine greater than I .2 mg/lOO ml) or hypertension 
(diastolic BP greater than 90 mm Hg). Two of the patients with autonomic 
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TABLE 1 
CHARACTERIZATION OF THE HEALTHY CONTROLS AND DIABETIC PATIENTS WHO PARTICIPATED 
IN THE In Vivo DBH ASSAY 
--- 
Normal Diabetics without Diabetics with 
subjects autonomic neuropathy autonomic neuropathy 
Number of participants 7 6 6 
Sex 3 males 2 males 2 males 
4 females 4 females 4 females 
Age range (years) 32-60 28-63 25-63 
Mean 44 40 37 
Body weight range (kg) 51.1-109 5 1 .O-78 47.3-81 
Mean 77 64 63 
neuropathy had nonproliferative retinopathy. None of the diabetics with- 
out autonomic neuropathy had clinically manifest complications. The 
autonomic neuropathy patients had a drop in systolic blood pressure of 
at least 20 mm Hg 15 set after shifting from the supine to the upright 
posure. In addition, these patients had a cardiac beat-to-beat variation 
on deep breathing of less than 12 (12) and/or a post-valsalva bradycardia 
tachycardia R-R interval ratio of less than 1 .I5 (13). 
[p -3H]DA (sp act 20 Wmmole, New England Nuclear, NET-131) was 
passed through a 0.2 p Millipore filter to protect against bacterial con- 
tamination, The isotope (500 @Z/70 kg) was infused slowly over 2 min 
into an antecubital vein to patients at the Clinical Research Center of 
the University of Michigan. Urine was collected for [3H]catecholamine 
metabolite determination for the first 6 hr after isotope administration 
in bottles containing 10 ml of 6 N HCI. The patients remained upright 
and ambulatory during the urine collection period, though they were 
allowed to sit down for lunch and a 5-min rest period each hour was 
permitted. The diabetics were maintained on their usual diet and insulin 
regimen on the day of the experiment. 
Four of the control patients participated in the in vivo assay twice, 
once with and once without disulfiram pre-reatment (5.5 mg/kg/day orally 
for 4 days). The [S-3H]DA was given 90 min after the last dose of 
disulfiram. There was at least a 5-week interval between the control 
period and the disuhiram treatment period. 
This study was approved by the University of Michigan Human Use 
Committee. Informed consent was obtained from all subjects prior to 
their participation. 
Assay of Total Body THO 
THO was lypohilized from whole blood and trapped according to the 
method of Stansell and Mojica (14). Total body THO was calculated (on 
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the assumption that intravascular THO equals extravascular THO) as 
described previously (1 I). 
Assay of [‘HjCatecholamines and [‘HKatecholamine Metabolites 
Endogenous to NE and HVA 
Urinary [‘Hlcatecholamines were extracted and fractionated by ion 
exchange (Dowex 5OW-X4) and alumina chromatography (15). Final sep- 
arations were performed with high-pressure liquid chromatography (HPLC) 
(16). Urinary HVA was purified by HPLC (16) and then assayed fluo- 
rometrically (17). Free urinary NE was purified by column chromatog- 
raphy (15) and then assayed fluorometrically (18). 
RESULTS 
DBH activity of the diabetic autonomic neuropathy patients did not 
differ significantly from that of the diabetics without neuropathy or the 
healthy controls (Fig. 1). There were no significant differences in [‘HINE 
metabolite excretion among these groups of subjects (Table 2) though 
the ratio of total r3H]NE metabolites to total [‘HIDA metabolites was 
slightly decreased in some of the autonomic neuropathy patients (Fig. 




























FIG. 1. In vivo DBH Assay in Control Subjects (N= 7) following disulfiram treatment 
(N=4), and in diabetic patients with (N=6) and without (N=6) autonomic neuropathy. 
The data indicate mean total body THO 2 SEM. expressed as percentage of administered 
isotope. Statistical analysis was performed as described under Results. Asterisks as defined 
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FIG. 2. [)H]NE metabolite excretion in control patients and diabetics, with and without 
autonomic neuropathy. Each point represents the ratio of total [‘HJNE metaboliteskotal 
[‘HIDA metabolites for a single patient. One-way analysis of variance revealed that this 
ratio was significantly decreased (P < 0.005) in the disulliram-treated patients specificJIy 
compared with the other three groups of patients (191. 
THO release and [3H]NE metabolite excretion (r = 0.68, P < 0.01, Fig. 
3). In order to assess the effect of disulfiram on these two indices of 
dopamine p-hydroxylation, a one way analysis of variance was performed 
and then the disulfiram pretreatment group was specifically compared 
with the other three groups (19). By this criteria, disulfiram treatment 
significantly decreased THO release (Fig. l), the excretion of many of 
the individual [3H]NE metaboiites (Table 2), and total [3H}NE metabolite 
excretion (Fig. 2). Disulfiram also inhibited aldehyde dehydrogenase as 
evidenced by the marked increase in the excretion of the minor neutral 
DA metabolite f3H]dihydroxyphenylethanol (DHPE) and the modest de- 
crease in free [3HJdihydroxyphenylacetic acid (DOPAC) excretion.3 
The free NE excretion of the autonomic neuropathy patients was quite 
variable, and only two of these patients (BB and GM) excreted low levels 
of free NE (Fig. 4). These patients did not exhibit decreased THO release 
from [P-3H]DA and, in fact, one of them (GM) had increased THO 
release. GM also had low HVA excretion (Fig. 5). There was a negative 
correlation between HVA excretion and THO release (r= - 50, P < 
0.05, Fig. 5). 
DISWSSlON 
Our data indicate that most patients with diabetic autonomic neuro- 
pathy hydroxyiate dopamine normally. This condition is thus distinct 
’ The disulfiram effect on aidehyde dehydrogenase should not affect tritium release and 
interfere with the in vivo DBH assay. This point is discussed in detail ekewhere (11). 
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FIG. 3. THO release and [‘H]NE metabolite excretion in controls (0) diabetes (m) and 
diabetic autonomic neuropathy (m. A highly significant correlation (r = 0.68, P < 0.01) 
was observed between THO release and [‘HJNE metabohte excretion. The regression 







FIG. 4. Free NE excretion in control subjects and diabetics, with and without autonomic 
neuropathy. There was no significant difference in the free NE excretion of these three 
groups of patients. 
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FIG. 5. Negative correlation between THO release from [p-3H]DA and endogenous 
urinary HVA. Symbols as defined in Fig. 3. The regression equation for the pooled data 
is Y = -.99X + 9.43, r = -0.501, P C 0.05). 
from idiopathic orthostatic hypotension where a deficit in dopamine p- 
hydroxylation has been described (9). Though some of the diabetics with 
autonomic neuropathy may have a mild impairment of DBH activity as 
evidenced by their slightly decreased [3H]NE metabolite excretion fol- 
lowing intravenous [p -3H]DA (Fig. 2), this deficit probably could not 
account for their postural hypotension. This is because some of the 
disulfiram-treated control subjects exhibited a greater decrease in [3H]NE 
metabolite excretion than did the neuropathy patients but had little or 
no change in their blood pressure as they shifted from a supine to an 
upright posture. 
Since we did not measure circulating NE and its response to postural 
stress, we cannot strictly categorize our patients into hypoadrenergic 
and hyperadrenergic autonomic neuropathy as defined previously (3). 
Urine was collected with the patients upright, however, and highly vari- 
able urinary NE levels were noted in the autonomic neuropathy group 
simulating the variability previously observed in plasma NE (3). Since 
the assumption of the upright posture has a similar effect on plasma NE 
and urinary NE (20), it is reasonable to assume that the two individuals 
in the present study (GM and BB) with low urinary NE had hypoad- 
renergic autonomic neuropathy. Neither of these patients had decreased 
DBH activity (as assessed from THO release from [B -‘HIDA) but of 
special interest is the fact that one patient (GM) had increased THO 
release (Figs. 3 and 5). Though the high THO release may represent 
enhanced DBH activity in his sympathetic neurons, this interpretation 
DBH AND DIABETIC AUTONOMIC NEUROPATHY 75 
of the data does not explain the low urinary NE. It thus seems more 
likely that the high THO release is the result of depletion of the pool 
of intraneuronal DA resulting in low endogenous substrate competing 
with [B - 3H]DA for DBH. In support of this conclusion is the fact that 
GM’s urinary HVA was low (Fig. 5). It is unlikely that a deficit in NE 
release is the cause of his low urinary NE since [3H]NE metabolite 
excretion was not decreased (Fig. 2). 
This negative correlation between THO release and HVA excretion 
(Fig. 5) suggests that alterations in the sympathetic neuronal DA pool 
may affect the in vivo essay of DBH. Though there are no available 
methods for resolving this issue in humans by determining the specific 
activity of the intraneuronal DA pool, the tritium release principle can 
nevertheless be used to clinically estimate the activity of catecholamine 
biosynthetic enzymes in disease states associated with low NE levels 
in blood and urine. This is possible because there are only two potentially 
regulatory enzymes involved in NE biosynthesis, tyrosine hydroxylase 
and DBH (5,6). Thus, low NE levels coupled with low THO release 
from [B - ‘HIDA suggest a deficit in dopamine B-hydroxylation, as ob- 
served in subjects treated with disulfiram (11). By contrast when low NE 
levels are coupled with high THO release, reasoning by exclusion sug- 
gests an abnormality in the other potentially regulatory NE biosynthetic 
enzyme, tyrosine hydroxylase.4 Moreover, decreased activity of the latter 
enzyme would be expected to lead to decreased endogenous DA com- 
peting with [B - 3H]DA for DBH, the result being high THO release. The 
presently described patient (GM) with low urinary NE, low urinary HVA, 
and high THO release exemplifies this pattern of results. Further studies, 
however, will be needed to establish the validity of this interpretation 
of high rates of THO release from [p - “HIDA. 
SUMMARY 
Dopamine B-hydroxylase (DBH) has been studied in healthy subjects 
and diabetic patients, some of whom had autonomic neuropathy. DBH 
was assayed by a recently described in vivo tritium release method 
(lo,1 1). Dopamine specifically labeled in the B position, [p - ‘HIDA, was 
given intravenously, and the time course of tritiated water (THO) release 
into the total body water was measure as an index of DBH activity in 
sympathetic neurons. We simultaneously assayed [‘Hlnorepinephrine 
metabolite excretion. 
The DBH activity of patients with autonomic neuropathy as a group 
did not differ significantly from that of diabetics without neuropathy or 
’ The third enzyme in the pathway, L. aromatic amino acid decarboxylase. is probably 
never rate limiting with respect to NE biosynthesis (5,6). 
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healthy controls. Our data do not support the suggestion (7) that a deficit 
in DBH activity is responsible for sympathetic neuronal dysfunction in 
diabetic autonomic neuropathy. This syndrome thus differs from idio- 
pathic orthostatic hypotension in which condition there is an impairment 
in the ability of sympathetic neurons to hydroxylate dopamine (9). 
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